Drug Profile
Andecaliximab - Gilead Sciences
Alternative Names: Anti-matrix metalloproteinase-9 monoclonal antibody; Anti-MMP9 monoclonal antibody; GS-5745Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Gilead Sciences
- Class Antineoplastics; Antiulcers; Monoclonal antibodies
- Mechanism of Action Matrix metalloproteinase 9 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease; Crohn's disease; Cystic fibrosis; Gastric cancer; Glioblastoma; Rheumatoid arthritis; Solid tumours; Ulcerative colitis
Most Recent Events
- 24 Dec 2020 Discontinued - Phase-I for Gastric cancer (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Japan (IV) (NCT02862535)
- 24 Dec 2020 Discontinued - Phase-I for Gastric cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Recurrent, Second-line therapy or greater) in Japan (IV) (NCT02862535)
- 24 Dec 2020 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02862535)